A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults

Not Applicable

Completed

• Conditions: Nicotine Dependence; Nicotine Addiction; Vaping; Nicotine Vaping; Nicotine Use Disorder
• Interventions: Behavioral: Smartphone app; Other: Text Message; Other: Survey Administration

• Registration Number: NCT05897242
• Lead Sponsor: Fred Hutchinson Cancer Center

Brief Summary

Almost one in ten young adults report current e-cigarette use, putting them at risk of developing nicotine addiction and long-term health effects of exposure to inhaled toxicants. Despite the need for effective treatments to help these young users quit, very few treatments targeting any type of tobacco use among young adults have been evaluated, particularly for young adults who vape and have unique treatment needs. To address these needs, this trial will evaluate a digital program for young adult e-cigarette users at all stages of readiness to quit called ACT on Vaping.

Detailed Description

OUTLINE:

Participants are randomized to 1 of 2 arms.

ARM I: Participants use the ACT on Vaping smartphone app and text messaging program and receive incentivized text messages assessing their vaping status.

ARM II: Participants receive incentivized text messages check-ins assessing their vaping status.

Study Timeline

• Study First Submitted: 2023-05-31
• Study First Submitted QC: 2023-05-31
• Study First Posted: 2023-06-09
• Study Start: 2024-01-04
• Primary Completion: 2024-04-26
• Study Completion: 2024-04-26
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-21
• Last Update Posted: 2024-05-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 61

Inclusion Criteria

• Age 18-30.
• Current weekly user of e-cigarette product(s).
• Owns an Android phone or iPhone.
• Has an email address.
• United States (US) resident, with a US mailing address.
• Willing to complete all study procedures.

Exclusion Criteria

• Currently using other tobacco cessation treatments at the time of screening, including pharmacotherapy or behavioral support (note: use of these treatments is allowable during trial participation).
• Member of the same household as another research participant.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm I (Act on Vaping app)	Smartphone app	Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.
Arm I (Act on Vaping app)	Survey Administration	Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.
Arm I (Act on Vaping app)	Text Message	Participants receive supportive messages and use the ACT on Vaping smartphone app. They also receive incentivized text message check-ins assessing their vaping status.
Arm II (Incentivized text message check-ins)	Text Message	Participants receive incentivized text messages check-ins assessing their vaping status.
Arm II (Incentivized text message check-ins)	Survey Administration	Participants receive incentivized text messages check-ins assessing their vaping status.

Primary Outcome Measures

Name	Time	Method
Change in readiness to quit	From baseline to 3 months post-randomization	Will evaluate differences of Contemplation Ladder scores.
Overall treatment satisfaction rating	At 3 months	Will calculate descriptive statistics (e.g., means, proportions) for the ACT on Vaping treatment group to assess treatment satisfaction (i.e., mean level of overall satisfaction with ACT on Vaping, with 3.5 on a 5-point scale being the "go" criterion).
Self-reported 24-hour quit attempt	At 3 months post-randomization	Will evaluate differences descriptively.
Cotinine-confirmed 30-day point prevalence abstinence from all nicotine and tobacco	At 3 months post-randomization	Will evaluate differences descriptively.

Trial Locations

Locations (1)

Fred Hutch/University of Washington Cancer Consortium; 🇺🇸 Seattle, Washington, United States